VEA
RLMD icon

Virtus ETF Advisers’s Relmada Therapeutics RLMD Stock Holding History

Virtus ETF Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,118
Closed -$226K – 478
2022
Q3 		$226K Buy
6,118
+50
+0.8% +$1.39K 0.09% 307
2022
Q2 		$115K Sell
6,068
-2,448
-29% -$53.4K 0.04% 397
2022
Q1 		$230K Sell
8,516
-499
-6% -$10.3K 0.1% 189
2021
Q4 		$203K Buy
9,015
+2,312
+34% +$51.4K 0.08% 202
2021
Q3 		$176K Sell
6,703
-353
-5% -$9.45K 0.08% 299
2021
Q2 		$226K Sell
7,056
-1,891
-21% -$65.7K 0.09% 259
2021
Q1 		$315K Buy
8,947
+164
+2% +$5.74K 0.13% 234
2020
Q4 		$282K Buy
8,783
+2,219
+34% +$76.3K 0.12% 243
2020
Q3 		$247K Sell
6,564
-899
-12% -$34.7K 0.13% 266
2020
Q2 		$334K Buy
+7,463
New +$316K 0.16% 282

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus ETF Advisers's RLMD Position: Q4 2022 in Review

Virtus ETF Advisers sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 6,118 shares — an estimated $226K sold.

Virtus ETF Advisers first reported a position in RLMD in Q2 2020 and held it in 10 quarters. The position peaked at $334K in Q2 2020. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Virtus ETF Advisers reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 6,118 Relmada Therapeutics shares in Q4 2022, an estimated $226K.
  • Virtus ETF Advisers first reported a position in Relmada Therapeutics in Q2 2020 and held it in 10 quarters.
  • Virtus ETF Advisers's Relmada Therapeutics position peaked at $334K in Q2 2020.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.